(NASDAQ: ALKS) Alkermes's forecast annual revenue growth rate of -2.18% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Alkermes's revenue in 2024 is $1,663,405,000.On average, 7 Wall Street analysts forecast ALKS's revenue for 2024 to be $253,462,346,339, with the lowest ALKS revenue forecast at $247,573,413,879, and the highest ALKS revenue forecast at $256,528,694,608. On average, 7 Wall Street analysts forecast ALKS's revenue for 2025 to be $253,739,692,720, with the lowest ALKS revenue forecast at $247,372,922,520, and the highest ALKS revenue forecast at $261,965,351,976.
In 2026, ALKS is forecast to generate $261,570,216,921 in revenue, with the lowest revenue forecast at $248,091,349,892 and the highest revenue forecast at $271,966,529,297.